DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study

Cardiovascular Diabetology

Volumn 13, Issue 1, 2014, Pages

  Nakamura, Kazufumi ^a   Oe, Hiroki ^a   Kihara, Hajime ^b   Shimada, Kenei ^c   Fukuda, Shota ^d   Watanabe, Kyoko ^e   Takagi, Tsutomu ^f   Yunoki, Kei ^a   Miyoshi, Toru ^a   Hirata, Kumiko ^g   Yoshikawa, Junichi ^h   Ito, Hiroshi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b Kihara Cardiovascular Clinic   (Japan)

^c Osaka Prefecture University   (Japan)

^d Osaka Ekisaikai Hospital   (Japan)

^e OKAYAMA SAISEIKAI GENERAL HOSPITAL   (Japan)

^f Takagi Cardiology Clinic   (Japan)

^g WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^h Nishinomiya Watanabe Cardiovascular Center   (Japan)

Author keywords

Alpha glucosidase inhibitor; CD34; Dipeptidyl peptidase 4 (DPP 4) inhibitors; Endothelial function; Flow mediated dilatation

Indexed keywords

C PEPTIDE; CD34 ANTIGEN; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; SITAGLIPTIN; SULFONYLUREA; VOGLIBOSE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLYCOSIDASE INHIBITOR; INOSITOL; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTERY DILATATION; ARTICLE; BODY MASS; BRACHIAL ARTERY; CONTROLLED STUDY; DIARRHEA; DIET RESTRICTION; DISEASE DURATION; DRUG EFFICACY; EDEMA; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL PROGENITOR CELL; EPIGASTRIC FULLNESS; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; MIDDLE AGED; PHYSIOLOGY; VASCULAR ENDOTHELIUM; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ENDOTHELIUM, VASCULAR; FEMALE; GLYCOSIDE HYDROLASE INHIBITORS; HUMANS; INOSITOL; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRAZINES; TRIAZOLES; YOUNG ADULT;

EID: 84905858733     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-014-0110-2     Document Type: Article

References (43)

1. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996, 39(12):1577-1583. 10.1007/s001250050617, 8960845.
2. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases?. Diabetes Care 2003, 26(3):688-696. 10.2337/diacare.26.3.688.
3. Kawano H, Motoyama T, Hirashima O, Hirai N, Miyao Y, Sakamoto T, Kugiyama K, Ogawa H, Yasue H. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 1999, 34(1):146-154. 10.1016/S0735-1097(99)00168-0, 10400004.
4. Wascher TC, Schmoelzer I, Wiegratz A, Stuehlinger M, Mueller-Wieland D, Kotzka J, Enderle M. Reduction of postchallenge hyperglycaemia prevents acute endothelial dysfunction in subjects with impaired glucose tolerance. Eur J Clin Invest 2005, 35(9):551-557. 10.1111/j.1365-2362.2005.01550.x, 16128861.
5. Martin AE, Montgomery PA. Acarbose: an alpha-glucosidase inhibitor. Am J Health Syst Pharm 1996, 53(19):2277-2290. quiz 2336-2277, 8893066.
6. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002, 359(9323):2072-2077. 10.1016/S0140-6736(02)08905-5, 12086760.
7. Hiki M, Shimada K, Kiyanagi T, Fukao K, Hirose K, Ohsaka H, Fukushima Y, Kume A, Matsumori R, Sumiyoshi K, Miyazaki T, Ohmura H, Kurata T, Miida T, Daida H. Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic patients with coronary heart disease (J-MACH). Circ J 2010, 74(7):1471-1478. 10.1253/circj.CJ-10-0013, 20519875.
8. Emoto T, Sawada T, Hashimoto M, Kageyama H, Terashita D, Mizoguchi T, Mizuguchi T, Motodi Y, Iwasaki M, Taira K, Okamoto H, Matsuo Y, Kim SK, Takarada A, Yokoyama M. Effect of 3-month repeated administration of miglitol on vascular endothelial function in patients with diabetes mellitus and coronary artery disease. Am J Cardiol 2012, 109(1):42-46. 10.1016/j.amjcard.2011.08.005, 21944671.
9. Shimabukuro M, Higa N, Chinen I, Yamakawa K, Takasu N. Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study. J Clin Endocrinol Metab 2006, 91(3):837-842. 10.1210/jc.2005-1566, 16368744.
10. Kato T, Inoue T, Node K. Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study. Cardiovasc Diabetol 2010, 9:12. 10.1186/1475-2840-9-12, 20334663.
11. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004, 25(1):10-16. 10.1016/S0195-668X(03)00468-8, 14683737.
12. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003, 290(4):486-494. 10.1001/jama.290.4.486, 12876091.
13. Hanefeld M, Schaper F, Koehler C. Effect of acarbose on vascular disease in patients with abnormal glucose tolerance. Cardiovasc Drugs Ther 2008, 22(3):225-231. 10.1007/s10557-008-6091-1, 18309462.
14. Seo C, Sakamoto M, Nishimura R, Tsujino D, Ando K, Morimoto A, Utsunomiya K. Comparison of glycemic variability in patients with type 2 diabetes given sitagliptin or voglibose: a continuous glucose monitoring-based pilot study. Diabetes Technol Ther 2013, 15(5):378-385. 10.1089/dia.2012.0262, 23634671.
15. Anagnostis P, Athyros VG, Adamidou F, Panagiotou A, Kita M, Karagiannis A, Mikhailidis DP. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes Metab 2011, 13(4):302-312. 10.1111/j.1463-1326.2010.01345.x, 21205117.
16. Nystrom T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahren B, Sjoholm A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004, 287(6):E1209-E1215. 10.1152/ajpendo.00237.2004, 15353407.
17. Liu L, Liu J, Wong WT, Tian XY, Lau CW, Wang YX, Xu G, Pu Y, Zhu Z, Xu A, Lam KS, Chen ZY, Ng CF, Yao X, Huang Y. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism. Hypertension 2012, 60(3):833-841. 10.1161/HYPERTENSIONAHA.112.195115, 22868389.
18. Pistrosch F, Schaper F, Passauer J, Koehler C, Bornstein SR, Hanefeld M. Effects of the alpha glucosidase inhibitor acarbose on endothelial function after a mixed meal in newly diagnosed type 2 diabetes. Horm Metab Res 2009, 41(2):104-108. 10.1055/s-0028-1103276, 19061152.
19. Ayaori M, Iwakami N, Uto-Kondo H, Sato H, Sasaki M, Komatsu T, Iizuka M, Takiguchi S, Yakushiji E, Nakaya K, Yogo M, Ogura M, Takase B, Murakami T, Ikewaki K. Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients. J Am Heart Assoc 2013, 2(1):e003277. 10.1161/JAHA.112.003277, 23525426.
20. Liao YF, Chen LL, Zeng TS, Li YM, Fan Y, Hu LJ, Ling Y. Number of circulating endothelial progenitor cells as a marker of vascular endothelial function for type 2 diabetes. Vasc Med 2010, 15(4):279-285. 10.1177/1358863X10367537, 20511292.
21. Fadini GP, Boscaro E, Albiero M, Menegazzo L, Frison V, de Kreutzenberg S, Agostini C, Tiengo A, Avogaro A. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care 2010, 33(7):1607-1609. 10.2337/dc10-0187, 20357375.
22. Mackie AR, Losordo DW. CD34-positive stem cells: in the treatment of heart and vascular disease in human beings. Tex Heart Inst J 2011, 38(5):474-485. 22163120.
23. Ishibashi Y, Matsui T, Maeda S, Higashimoto Y, Yamagishi S. Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cardiovasc Diabetol 2013, 12:125. 10.1186/1475-2840-12-125, 23984879.
24. Matsubara J, Sugiyama S, Akiyama E, Iwashita S, Kurokawa H, Ohba K, Maeda H, Fujisue K, Yamamoto E, Kaikita K, Hokimoto S, Jinnouchi H, Ogawa H. Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Circ J 2013, 77(5):1337-1344. 10.1253/circj.CJ-12-1168, 23386232.
25. Shiraki A, Oyama J, Komoda H, Asaka M, Komatsu A, Sakuma M, Kodama K, Sakamoto Y, Kotooka N, Hirase T, Node K. The glucagon-like peptide 1 analog liraglutide reduces TNF-alpha-induced oxidative stress and inflammation in endothelial cells. Atherosclerosis 2012, 221(2):375-382. 10.1016/j.atherosclerosis.2011.12.039, 22284365.
26. Iwamoto Y, Taniguchi T, Nonaka K, Okamoto T, Okuyama K, Arjona Ferreira JC, Amatruda J. Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Endocr J 2010, 57(5):383-394. 10.1507/endocrj.K09E-272, 20332588.
27. Matsumoto K, Yano M, Miyake S, Ueki Y, Yamaguchi Y, Akazawa S, Tominaga Y. Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients. Diabetes Care 1998, 21(2):256-260. 10.2337/diacare.21.2.256, 9539992.
28. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009, 53(6):982-992. 10.1053/j.ajkd.2008.12.034, 19339088.
29. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002, 39(2):257-265. 10.1016/S0735-1097(01)01746-6, 11788217.
30. Yunoki K, Nakamura K, Miyoshi T, Enko K, Kohno K, Morita H, Kusano KF, Ito H. Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction. Atherosclerosis 2011, 217(2):486-491. 10.1016/j.atherosclerosis.2011.04.019, 21592480.
31. Yunoki K, Nakamura K, Miyoshi T, Enko K, Kubo M, Murakami M, Hata Y, Kohno K, Morita H, Kusano KF, Ito H. Impact of hypertriglyceridemia on endothelial dysfunction during statin +/-ezetimibe therapy in patients with coronary heart disease. Am J Cardiol 2011, 108(3):333-339. 10.1016/j.amjcard.2011.03.049, 21545981.
32. Noda Y, Miyoshi T, Oe H, Ohno Y, Nakamura K, Toh N, Kohno K, Morita H, Kusano K, Ito H. Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non- diabetic subjects: a preliminary report. Cardiovasc Diabetol 2013, 12(1):8. 10.1186/1475-2840-12-8, 23298374.
33. Charakida M, de Groot E, Loukogeorgakis SP, Khan T, Luscher T, Kastelein JJ, Gasser T, Deanfield JE. Variability and reproducibility of flow-mediated dilatation in a multicentre clinical trial. Eur Heart J 2013, 34(45):3501-3507. 10.1093/eurheartj/eht223, 23821401.
34. Lind L. Impact of ageing on the measurement of endothelium-dependent vasodilation. Pharmacol Rep 2006, 58(Suppl):41-46. 17332670.
35. Maruhashi T, Soga J, Fujimura N, Idei N, Mikami S, Iwamoto Y, Kajikawa M, Matsumoto T, Hidaka T, Kihara Y, Chayama K, Noma K, Nakashima A, Goto C, Tomiyama H, Takase B, Yamashina A, Higashi Y. Relationship between flow-mediated vasodilation and cardiovascular risk factors in a large community-based study. Heart 2013, 99(24):1837-1842. 10.1136/heartjnl-2013-304739, 24153417.
36. Kubota Y, Miyamoto M, Takagi G, Ikeda T, Kirinoki-Ichikawa S, Tanaka K, Mizuno K. The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes. J Korean Med Sci 2012, 27(11):1364-1370. 10.3346/jkms.2012.27.11.1364, 23166419.
37. Scheen AJ. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes. Postgrad Med 2013, 125(3):7-20. 10.3810/pgm.2013.05.2659, 23748503.
38. Hausenloy DJ, Whittington HJ, Wynne AM, Begum SS, Theodorou L, Riksen N, Mocanu MM, Yellon DM. Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner. Cardiovasc Diabetol 2013, 12(1):154. 10.1186/1475-2840-12-154, 24148218.
39. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013, 369(14):1317-1326. 10.1056/NEJMoa1307684, 23992601.
40. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013, 369(14):1327-1335. 10.1056/NEJMoa1305889, 23992602.
41. Iwamoto Y, Tajima N, Kadowaki T, Nonaka K, Taniguchi T, Nishii M, Arjona Ferreira JC, Amatruda JM. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes Obes Metab 2010, 12(7):613-622. 10.1111/j.1463-1326.2010.01197.x, 20590736.
42. Sakamoto Y, Oyama J, Ikeda H, Kuroki S, Gondo S, Iwamoto T, Uchida Y, Kodama K, Hiwatashi A, Shimomura M, Taguchi I, Inoue T, Node K. Effects of sitagliptin beyond glycemic control: focus on quality of life. Cardiovasc Diabetol 2013, 12:35. 10.1186/1475-2840-12-35, 23432786.
43. Engel SS, Golm GT, Shapiro D, Davies MJ, Kaufman KD, Goldstein BJ. Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovasc Diabetol 2013, 12:3. 10.1186/1475-2840-12-3, 23286208.